|
|
The second half of the 20th century has seen huge advances in the field of biotechnology and the tendency has continued unabated in the 21st century broadening the pharmaceutical palette with various APIs (active pharmaceutical ingredients) of biotechnological origin (Figure 1.). The broad spectrum of biotechnology based API-s or biodrugs includes proteins, peptides, whole cells, nucleic acids, viral particles and vaccines [1] all being produced in a biotechnological way where the end product, the biodrug itself is usually in a water solution or suspension.
|